Nasal Drug Delivery Technology Market Report 2026

Nasal Drug Delivery Technology Market Overview

• Nasal Drug Delivery Technology market size has reached to $85.23 billion in 2025 • Expected to grow to $129.23 billion in 2030 at a compound annual growth rate (CAGR) of 8.8% • Growth Driver: The Rise In Chronic Disease Prevalence Fueling Market Growth Due To Increasing Demand For Noninvasive And Rapid Drug Delivery Solutions • Market Trend: Strategic Collaborations Drive Advancements In Nasal Powder Delivery Devices • North America was the largest region in 2025.

What Is Covered Under Nasal Drug Delivery Technology Market?

The nasal drug delivery technology refers to administering pharmaceuticals through the nasal cavity to attain therapeutic drug levels in the blood as quickly as possible and the potential for direct drug delivery to the brain via the olfactory neurons. Nasal drug delivery methods circumvent the blood-brain barrier (BBB) and undergo minimal hepatic and intestinal processing. The main type of dosage forms for nasal drug delivery technology includes nasal spray, nasal drops, nasal gels and ointments, nasal powders, and others. Nasal spray refers to nasal drug delivery devices that force a large quantity of tiny liquid drops to cleanse the nose or administer medication to the body. It is available in two main types of containers that are pressurized and non-pressurized and is used in various applications such as allergic and non-allergic rhinitis, nasal congestion, asthma, vaccination, and others. It is available through various distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and is being used by end-users such as home care settings and hospitals.

What Is The Nasal Drug Delivery Technology Market Growth Forecast?

The nasal drug delivery technology market size is expected to see strong growth in the next few years. It will grow to $129.23 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to increasing investments in CNS drug development, rising demand for rapid-onset therapies, expansion of nasal vaccine research, growing adoption of patient-friendly delivery systems, continuous innovation in nasal formulation technologies. Major trends in the forecast period include increasing adoption of nasal spray drug formulations, rising focus on brain-targeted drug delivery, growing development of novel nasal drug devices, expansion of vaccine and emergency therapeutic applications, enhanced emphasis on rapid drug absorption.

Global Nasal Drug Delivery Technology Market Segmentation

1) By Dosage Form: Nasal Spray, Nasal Drops, Nasal Gels And Ointments, Nasal Powders, Other Dosage Forms 2) By Container Type: Pressurized Containers, Non-Pressurized Containers 3) By Therapeutic Application: Allergic And Non-Allergic Rhinitis, Nasal Congestion, Vaccination, Other Therapeutic Applications 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 5) By End User: Home Care Settings, Hospitals Subsegments: 1) By Nasal Spray: Metered-Dose Spray, Non-Metered-Dose Spray 2) By Nasal Drops: Liquid Nasal Drops, Gel-Based Nasal Drops 3) By Nasal Gels and Ointments: Hydrogel Formulations, Oil-Based Ointments 4) By Nasal Powders: Dry Powder Inhalers (DPI), Spray-Dried Powders 5) By Other Dosage Forms: Nasal Patches, Nasal Inserts

What Is The Driver Of The Nasal Drug Delivery Technology Market?

The rising incidence of chronic diseases is expected to propel the growth of the nasal drug delivery technology market going forward. Chronic diseases are long-term medical conditions that last for a year or more and require ongoing medical management, often limiting daily functioning and lowering overall quality of life. The rise in chronic disease prevalence is driven by aging populations, sedentary lifestyles, and increased exposure to environmental risk factors, all of which heighten the need for more effective and patient-friendly therapeutic delivery methods. Nasal drug delivery technologies support improved treatment outcomes by providing a noninvasive, fast-acting, and efficient route for administering medications, particularly for chronic rhinosinusitis and other persistent airway disorders that require targeted nasal absorption and enhanced mucociliary clearance. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023, marking an 18% increase from 3,065,825 cases in 2022. Therefore, the rising incidence of chronic diseases is driving the growth of the nasal drug delivery technology industry.

Key Players In The Global Nasal Drug Delivery Technology Market

Major companies operating in the nasal drug delivery technology market are AptarGroup Inc., Becton Dickinson and Company, GlaxoSmithKline plc, Johnson & Johnson Private Limited, Novartis AG, Pfizer Inc., 3M Company, Cadila Healthcare Limited, Neurelis Inc., OptiNose Inc., Bausch Health Companies Inc., Naveh Pharma Ltd., Teva Pharmaceutical Industries Ltd., Consort Medical plc, Douglas Pharmaceuticals Ltd., ENT Technologies Pty Ltd, Merck & Co Inc, Sanofi SA, AstraZeneca plc, Boehringer Ingelheim International GmbH, Bayer AG, Abbott Laboratories, Eli Lilly and Company, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Roche Holding AG, Allergan plc

Global Nasal Drug Delivery Technology Market Trends and Insights

Major companies operating in the nasal drug delivery technology market are focused on the collaborative development of technologically advanced products such as nasal powder delivery devices, enhancing precision, usability, and therapeutic efficacy, reflecting a strategic emphasis on innovation within the nasal drug delivery sector. A nasal powder delivery device is a technology designed for the administration of powdered medications through the nasal route, facilitating targeted drug delivery for local, systemic, or nose-to-brain applications. For instance, in November 2023, Hovione LLC., a Portugal-based pharmaceutical company specializing in the contract development and manufacturing of active pharmaceutical ingredients (APIs) and drug product intermediates, collaborated with Industrial Design Consultancy (IDC), a UK-based product design and development company, to develop an innovative nasal powder delivery device technology for local, systemic, and nose-to-brain drug delivery, aiming to expedite the development and release of two novel active nasal powder delivery devices, one single-use and one multidose. These devices provide versatile and precise nasal deposition options, ensuring optimal usability and reliability, and have the potential to streamline drug product development and manufacturing through compatibility with standard capsules and filling equipment. Hovione will exclusively offer these devices as part of its comprehensive solution for nasal drug development and manufacturing.

What Are Latest Mergers And Acquisitions In The Nasal Drug Delivery Technology Market?

In October 2024, Aptargroup Inc., a US-based global drug delivery systems company, acquired the device-technology assets of SipNose LTD. Nasal Delivery Systems for an undisclosed amount. Through this acquisition, Aptar aims to strengthen its intranasal and central nervous system (CNS) drug delivery capabilities by integrating SipNose’s specialized platforms designed for local, systemic, and nose-to-brain delivery. SipNose LTD. is an Israel-based company focused on developing targeted intranasal drug delivery technologies.

Regional Outlook

North America was the largest region in the nasal drug delivery technology market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Nasal Drug Delivery Technology Market?

The nasal drug delivery technology market consists of revenues earned by entities by providing services such as intranasal drug delivery services, brain-targeted therapy, and mucosal vaccination. The market value includes the value of related goods sold by the service provider or included within the service offering. The nasal drug delivery technology market also includes sales of catheter-delivered drugs, nebulizers, and pressurized metered-dose inhalers (PMDIs) equipment which are used in providing nasal drug delivery technology services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.